A single-clinician workflow means one authorized clinician completes and documents the waste event without a second person observing it. Evaluating that approach starts with the type of waste, the applicable requirements, and the controls your hospital will use.
Pharmaceutical wastage and inventory disposal are different
DEA distinguishes controlled medication remaining after immediate administration from controlled substances still held in a practitioner’s inventory. The distinction depends on how the medication was dispensed and used, not simply whether its container is open.1
| Pharmaceutical wastage | Inventory disposal |
|---|---|
| An unusable remainder after a medication ordered for immediate administration is given at the practitioner’s registered location, such as liquid left in a single-dose syringe. | Controlled substances remaining in stock, such as expired inventory or medication still held in a multi-dose vial.1 |
| Destruction must be documented. Qualifying remnants do not require a DEA Form 41, but remain subject to applicable disposal and security obligations.32 | Part 1317 inventory-disposal requirements apply. On-site destruction under § 1317.95(d) requires two employees to handle or observe handling and personally witness destruction.24 |
What DEA clarified in October 2014
In its October 17, 2014 Dear Practitioner letter, DEA explained that the new Part 1317 disposal requirements applied to practitioner inventory, rather than pharmaceutical wastage. It also strongly encouraged diversion controls and described two-person witnessing and documentation as a common institutional policy.1
The distinction matters: the letter did not impose Part 1317’s inventory-destruction procedure on routine pharmaceutical wastage. It also did not approve every single-clinician workflow. DEA’s 2023 manual continues to distinguish the two situations and points to the remaining recordkeeping and disposal obligations.2
State requirements and hospital policy determine the local approach
For a hospital considering a change, state law, licensing-board requirements, and its own policies are central. Federal requirements remain in force; compliance with DEA rules does not override other applicable law.5
Professional guidance also informs that decision. ASHP’s 2022 guidelines call for independent witnessing and documentation, with a specific exception in Appendix B for waste returned to pharmacy for assay and wasting. That is not a general endorsement of single-clinician point-of-care wasting.6
Have pharmacy, nursing, anesthesia, compliance, and legal leaders confirm the requirements for the proposed setting. A witness required by law or hospital policy remains required unless a lawful policy change or applicable authorization permits the alternative.
How WasteWitness adds real evidence
Within an authorized workflow, WasteWitness provides measurements from the waste itself. Raman spectroscopy and MED-ID assess drug identity and concentration; onboard hardware measures volume separately.
- Drug identity: Assess whether the expected medication is present within supported analytical capabilities.
- Concentration: Identify a measured strength that differs from what was expected.
- Volume: Compare the measured amount with the documented waste.
- Event context: Connect the findings with the signed-in user, time, location, and available medication records.
Authorized administrators can review individual findings and recurring patterns. This gives pharmacy, diversion, and compliance teams evidence to support follow-up and document their review.
Chemical verification supports the control process. It does not establish what was administered to the patient, constitute a human witness, or authorize a change to a required witnessing procedure.
Evaluate a defined workflow
If the applicable requirements permit a single-clinician approach, define eligible medications and care areas, authentication, disposal controls, result review, and an exception process for unavailable or inconclusive analysis. Confirm the intended WasteWitness configuration with PharmID.
Measure the staff experience and the usefulness of the evidence together. The goal is a practical wasting workflow backed by documented verification and accountable oversight.
Read the original sources
- DEA Dear Practitioner letter, October 17, 2014
Historical clarification of pharmaceutical wastage versus practitioner inventory. Archived copy hosted by the National Waste & Recycling Association.
Read the October 2014 letter (PDF) (opens in a new tab) - DEA Practitioner’s Manual, 2023 edition
See Disposal of Controlled Substances and Pharmaceutical Wastage, pp. 39 - 40. The manual is guidance; applicable laws and regulations govern.
Read the DEA manual (PDF) (opens in a new tab) - 21 CFR 1304.21(e): Record of destruction
Recordkeeping and the Form 41 exception for qualifying remnants after immediate administration. eCFR reviewed November 18, 2026.
Read the recordkeeping rule (opens in a new tab) - 21 CFR 1317.95(d): On-site destruction
Two-employee handling and witnessing requirements for on-site destruction subject to this provision. eCFR reviewed November 18, 2026.
Read the destruction procedures (opens in a new tab) - 21 CFR 1307.02: Application of State law and other Federal law
Compliance with DEA regulations does not authorize conduct prohibited by other applicable federal or state law. eCFR reviewed November 18, 2026.
Read the rule on other applicable laws (opens in a new tab) - ASHP Guidelines on Preventing Diversion of Controlled Substances
Clark J, et al. 2022. See Returns, waste, and disposal, pp. 2291 - 2292, and Appendix B, p. 2305, including the return-to-pharmacy-for-assay exception.
Read the ASHP guidelines (PDF) (opens in a new tab)
